<DOC>
	<DOCNO>NCT00844519</DOCNO>
	<brief_summary>The purpose study determine potentially beneficial aspect CCR5 inhibition inflammation endothelial function measure brachial artery reactivity antiretroviral treat HIV patient undetectable viral load .</brief_summary>
	<brief_title>Effect Maraviroc Endothelial Function HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Stable antiretroviral therapy least 12 month 2 . All plasma HIV RNA level within past year must level detection ( &lt; 50 copy RNA/mL ) , although isolated single value &gt; 50 &lt; 200 copy allow . 3 . Screening plasma HIV RNA level &lt; 50 copy RNA/mL 4 . &gt; 90 % adherence therapy within precede 30 day , determine selfreport 5 . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . 1 . Ongoing prior use integrase inhibitor R5 inhibitor . 2 . Patients plan modify exist antiretroviral therapy next 24 week reason 3 . Serious illness require hospitalization parental antibiotic within precede 3 month 4 . Concurrent recent exposure immunomodulatory drug 5 . Advanced liver disease active hepatitis B C 6 . Patients systolic blood pressure &lt; 100/70 7 . Starting stop statin therapy trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Treatment Experienced</keyword>
	<keyword>CCR5 receptor</keyword>
	<keyword>maraviroc</keyword>
</DOC>